BIOMAT Database Logo BIOMAT Database Logo

C-peptide suppression test and sulphonylurea-induced factitious hypoglycaemia. 1982

J S Harrop, and P R Golding, and P Goodall, and V M Leveau, and G A Steele, and A R Ingle

UI MeSH Term Description Entries
D007003 Hypoglycemia A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH. Fasting Hypoglycemia,Postabsorptive Hypoglycemia,Postprandial Hypoglycemia,Reactive Hypoglycemia,Hypoglycemia, Fasting,Hypoglycemia, Postabsorptive,Hypoglycemia, Postprandial,Hypoglycemia, Reactive
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007340 Insulinoma A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA. Adenoma, beta-Cell,Insuloma,beta-Cell Tumor,Adenoma, beta Cell,Adenomas, beta-Cell,Insulinomas,Insulomas,Tumor, beta-Cell,Tumors, beta-Cell,beta Cell Tumor,beta-Cell Adenoma,beta-Cell Adenomas,beta-Cell Tumors
D008297 Male Males
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D005162 Factitious Disorders Disorders characterized by physical or psychological symptoms that are not real, genuine, or natural. Ganser Syndrome,Pseudodementia,Pseudopsychosis,Disorders, Factitious,Syndrome, Ganser
D005905 Glyburide An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide Glibenclamide,Daonil,Diabeta,Euglucon 5,Euglucon N,Glybenclamide,HB-419,HB-420,Maninil,Micronase,Neogluconin,HB 419,HB 420,HB419,HB420

Related Publications

J S Harrop, and P R Golding, and P Goodall, and V M Leveau, and G A Steele, and A R Ingle
Factitious hypoglycaemia documented by a modified assay for the measurement of plasma sulphonylurea.
May 1995, Diabetic medicine : a journal of the British Diabetic Association,
J S Harrop, and P R Golding, and P Goodall, and V M Leveau, and G A Steele, and A R Ingle
Factitious hypoglycaemia.
December 2009, Internal medicine journal,
J S Harrop, and P R Golding, and P Goodall, and V M Leveau, and G A Steele, and A R Ingle
Factitious hypoglycaemia.
June 1978, Lancet (London, England),
J S Harrop, and P R Golding, and P Goodall, and V M Leveau, and G A Steele, and A R Ingle
Prevalence of factitious hypoglycaemia associated with sulphonylurea drugs in France in the year 2000.
November 2002, British journal of clinical pharmacology,
J S Harrop, and P R Golding, and P Goodall, and V M Leveau, and G A Steele, and A R Ingle
A case of severe relapsing sulphonylurea-induced hypoglycaemia.
December 2019, BMJ case reports,
J S Harrop, and P R Golding, and P Goodall, and V M Leveau, and G A Steele, and A R Ingle
Glucagon in sulphonylurea hypoglycaemia?
February 1968, Lancet (London, England),
J S Harrop, and P R Golding, and P Goodall, and V M Leveau, and G A Steele, and A R Ingle
Glucagon in sulphonylurea hypoglycaemia.
May 1968, Lancet (London, England),
J S Harrop, and P R Golding, and P Goodall, and V M Leveau, and G A Steele, and A R Ingle
Glucagon in sulphonylurea hypoglycaemia?
April 1968, Lancet (London, England),
J S Harrop, and P R Golding, and P Goodall, and V M Leveau, and G A Steele, and A R Ingle
C-peptide suppression test and recurrent insulinoma.
March 1989, The American journal of medicine,
J S Harrop, and P R Golding, and P Goodall, and V M Leveau, and G A Steele, and A R Ingle
C-peptide suppression test for insulinoma.
July 1977, The Journal of laboratory and clinical medicine,
Copied contents to your clipboard!